Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4809649 | 0.91 | POLB (0.41) | KDM4EKMT2AMEN1ADAM17SMN1; SMN2 | |
| SCHEMBL4817042 | 0.89 | ADAM17 (0.45) | KDM4EADAM17SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4807371 | 0.88 | KDM4E (0.46) | KDM4EKMT2AMEN1ADAM17SMN1; SMN2 | |
| SCHEMBL4811693 | 0.88 | KDM4E (0.37) | KDM4EKMT2AMEN1ADAM17ALDH1A1 | |
| SCHEMBL4814688 | 0.88 | LMNA (0.47) | KDM4EKMT2AMEN1LMNANPC1 | |
| SCHEMBL4813521 | 0.85 | KDM4E (0.44) | KDM4EKMT2AMEN1ADAM17SMN1; SMN2 | |
| SCHEMBL4811204 | 0.85 | KDM4E (0.46) | KDM4EKMT2AMEN1ADAM17SMN1; SMN2 | |
| SCHEMBL4812190 | 0.83 | ADAM17 (0.44) | KDM4EKMT2AMEN1ADAM17SMN1; SMN2 | |
| SCHEMBL4806545 | 0.83 | MEN1 (0.42) | KDM4EKMT2AMEN1ADAM17SMN1; SMN2 | |
| SCHEMBL4807305 | 0.83 | KDM4E (0.51) | KDM4EKMT2AMEN1ADAM17SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388103-B2 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2008-06-17 | — | — | US | disclosed |
| US-20060094843-A1 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2006-05-04 | — | — | US | disclosed |
| WO-2006045246-A1 | CYCLOPENTANE CARBOXYLATE COMPOUNDS, PROCESS AND INTERMEDIATES FOR PREPARING THE SAME AND USE THEREOF | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094843-A1 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | C5, C1S, AKR1C3 | KDM4E 2912/4885KMT2A 4572/4885MEN1 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.